Kairos Pharma, Ltd. (KAPA) Stock Price

KAPAStock
$0.2580.34%52W
Market Cap$5.88M
P/E
PEG Ratio
Div yield
Beta3.13

KAPA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-70.98%
Price vs S&P 500 (4W)-27.73%
VGM Score8.33

KAPA Earnings Surprise History

Q2 25-0.08est. -0.05
Q3 25-0.07est. -0.07
Q4 25-0.07est. 0.03
Q1 26-0.08est. -0.07

KAPA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
4.13
4.13
4.13

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
KAPAKairos Pharma, Ltd.
F$0.25
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Kairos Pharma, Ltd.

Kairos Pharma is a clinical-stage biopharmaceutical company developing cancer immunotherapies designed to overcome immune suppression and drug resistance. Its pipeline includes antibody and small molecule candidates targeting prostate cancer, lung cancer, breast cancer, and glioblastoma.